Literature DB >> 31843268

A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection.

Marina R Pulido1, Meritxell García-Quintanilla1, Jerónimo Pachón2, Michael J McConnell3.   

Abstract

Outer membrane vesicles (OMVs) were isolated from an Acinetobacter strain deficient in lipopolysaccharide (LPS) due to a mutation in lpxD (IB010). Two immunizations with 10 µg of IB010 OMVs elicited total IgG, IgM, IgG1 and IgG2c titers similar to those observed after immunization with OMVs derived from the parental strain (ATCC 19606), and IB010 OMVs plus purified LPS. Immunization with IB010 OMVs resulted in significantly reduced post-infection spleen bacterial loads and serum IL-1β and IL-6 levels compared to control mice in a disseminated sepsis model. Mice immunized with 10 µg IB010 OMVs demonstrated significant, but partial, protection (75%) against infection, whereas mice immunized with ATCC 19606 OMVs or IB010 OMVs plus purified LPS were completely protected. Immunization of mice with 100 µg of IB010 OMVs completely protected mice from infection. This study demonstrates that LPS deficient A. baumannii produces OMVs, and that immunization with these OMVs elicits protective immunity against infection.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Lipopolysaccharide; Outer membrane vesicles; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 31843268     DOI: 10.1016/j.vaccine.2019.11.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Extracellular vesicles of bacteria as potential targets for immune interventions.

Authors:  Yizhi Peng; Sheng Yin; Min Wang
Journal:  Hum Vaccin Immunother       Date:  2020-09-01       Impact factor: 3.452

2.  Thioredoxin-mediated alteration of protein content and cytotoxicity of Acinetobacter baumannii outer membrane vesicles.

Authors:  Swathi Shrihari; Holly C May; Jieh-Juen Yu; Sara B Papp; James P Chambers; M Neal Guentzel; Bernard P Arulanandam
Journal:  Exp Biol Med (Maywood)       Date:  2021-10-29

3.  In vivo hitchhiking of immune cells by intracellular self-assembly of bacteria-mimetic nanomedicine for targeted therapy of melanoma.

Authors:  Cheng Gao; Qingfu Wang; Junyan Li; Cheryl H T Kwong; Jianwen Wei; Beibei Xie; Siyu Lu; Simon M Y Lee; Ruibing Wang
Journal:  Sci Adv       Date:  2022-05-11       Impact factor: 14.957

Review 4.  Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates.

Authors:  Felix Behrens; Teresa C Funk-Hilsdorf; Wolfgang M Kuebler; Szandor Simmons
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 5.  Vaccine development to control the rising scourge of antibiotic-resistant Acinetobacter baumannii: a systematic review.

Authors:  Ravinder Singh; Neena Capalash; Prince Sharma
Journal:  3 Biotech       Date:  2022-03-02       Impact factor: 2.406

Review 6.  Promising Acinetobacter baumannii Vaccine Candidates and Drug Targets in Recent Years.

Authors:  Yong Chiang Tan; Chandrajit Lahiri
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

7.  Outer Membrane Vesicles of Helicobacter pylori 7.13 as Adjuvants Promote Protective Efficacy Against Helicobacter pylori Infection.

Authors:  Zifan Song; Biaoxian Li; Yingxuan Zhang; Ruizhen Li; Huan Ruan; Jing Wu; Qiong Liu
Journal:  Front Microbiol       Date:  2020-06-23       Impact factor: 5.640

8.  Outer Membrane Vesicles From Brucella melitensis Modulate Immune Response and Induce Cytoskeleton Rearrangement in Peripheral Blood Mononuclear Cells.

Authors:  Eric Daniel Avila-Calderón; Olín Medina-Chávez; Leopoldo Flores-Romo; José Manuel Hernández-Hernández; Luis Donis-Maturano; Ahidé López-Merino; Beatriz Arellano-Reynoso; Ma Guadalupe Aguilera-Arreola; Enrico A Ruiz; Zulema Gomez-Lunar; Sharon Witonsky; Araceli Contreras-Rodríguez
Journal:  Front Microbiol       Date:  2020-10-19       Impact factor: 5.640

Review 9.  Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.

Authors:  Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

10.  Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice.

Authors:  Xin Li; Chao Pan; Zhicheng Liu; Peng Sun; Xiaoting Hua; Erling Feng; Yunsong Yu; Jun Wu; Li Zhu; Hengliang Wang
Journal:  Microb Biotechnol       Date:  2021-03-23       Impact factor: 5.813

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.